Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | RXRG | P48443 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CFD | P00746 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1883666 | 0.89 | ALDH1A1 (0.58) | RXRARXRBRXRGALDH1A1MAPT | |
| SCHEMBL9360555 | 0.89 | GAA (0.56) | ALDH1A1MAPTGAATSHRNFKB1 | |
| SCHEMBL6221035 | 0.89 | GAA (0.56) | ALDH1A1MAPTGAATSHRNFKB1 | |
| Hydrochloric Acid SCHEMBL2525777 | 0.87 | ALDH1A1 (0.57) | RXRARXRBRXRGALDH1A1MAPT | |
| Methane SCHEMBL10372267 | 0.87 | GAA (0.54) | ALDH1A1MAPTGAATSHRNFKB1 | |
| Bromide SCHEMBL10998875 | 0.87 | ALDH1A1 (0.57) | RXRARXRBRXRGALDH1A1MAPT | |
| SCHEMBL31321633 | 0.86 | AKT1 (0.54) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3327028 | 0.84 | GAA (0.64) | RXRARXRBRXRGALDH1A1MAPT | |
| SCHEMBL2729631 | 0.84 | PTGS1 (0.64) | ALDH1A1MAPTGAATSHRNFKB1 | |
| SCHEMBL9865963 | 0.84 | ALOX15 (0.60) | ALDH1A1GAATSHRNFKB1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981931-B2 | Pharmaceutical compositions of short-acting sedative hypnotic agent | THERAVANCE, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981931-B2 | Pharmaceutical compositions of short-acting sedative hypnotic agent | THERAVANCE, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981931-B2 | Pharmaceutical compositions of short-acting sedative hypnotic agent | THERAVANCE, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7939689-B2 | Short-acting sedative hypnotic agents for anesthesia and sedation | THERAVANCE, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939689-B2 | Short-acting sedative hypnotic agents for anesthesia and sedation | THERAVANCE, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7790766-B2 | Comprising [4-[(N,N-diethylcarbamoyl)methoxy]-3-ethoxyphenyl]acetic acid propyl ester, a water-immiscible solvent, an emulsifier, a tonicity modifier, 0.05-0.2% by weight histidine, and water,wherein pH is greater than 7 and wherein composition contains a preservative | THERAVANCE, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790766-B2 | Comprising [4-[(N,N-diethylcarbamoyl)methoxy]-3-ethoxyphenyl]acetic acid propyl ester, a water-immiscible solvent, an emulsifier, a tonicity modifier, 0.05-0.2% by weight histidine, and water,wherein pH is greater than 7 and wherein composition contains a preservative | THERAVANCE, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790766-B2 | Comprising [4-[(N,N-diethylcarbamoyl)methoxy]-3-ethoxyphenyl]acetic acid propyl ester, a water-immiscible solvent, an emulsifier, a tonicity modifier, 0.05-0.2% by weight histidine, and water,wherein pH is greater than 7 and wherein composition contains a preservative | THERAVANCE, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100076079-A1 | Pharmaceutical Compositions Of Short-Acting Sedative Hypnotic Agent | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-03-25 | — | — | US | disclosed |
| US-20100076079-A1 | Pharmaceutical Compositions Of Short-Acting Sedative Hypnotic Agent | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-03-25 | — | — | US | disclosed |
| US-20090253787-A1 | SHORT-ACTING SEDATIVE HYPNOTIC AGENTS FOR ANESTHESIA AND SEDATION | THERAVANCE, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253787-A1 | SHORT-ACTING SEDATIVE HYPNOTIC AGENTS FOR ANESTHESIA AND SEDATION | THERAVANCE, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| EP-1648413-B1 | PHARMACEUTICAL COMPOSITIONS OF SHORT-ACTING SEDATIVE HYPNOTIC AGENT | THERAVANCE INC (US) | 2009-10-07 | — | — | EP | disclosed |
| US-7514425-B2 | Short-acting sedative hypnotic agents for anesthesia and sedation | THERAVANCE, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514425-B2 | Short-acting sedative hypnotic agents for anesthesia and sedation | THERAVANCE, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1648413-A2 | PHARMACEUTICAL COMPOSITIONS OF SHORT-ACTING SEDATIVE HYPNOTIC AGENT | Theravance, Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005009420-A2 | PHARMACEUTICAL COMPOSITIONS OF SHORT-ACTING SEDATIVE HYPNOTIC AGENT | THERAVANCE, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009420-A2 | PHARMACEUTICAL COMPOSITIONS OF SHORT-ACTING SEDATIVE HYPNOTIC AGENT | THERAVANCE, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020674-A1 | Comprising [4-[(N,N-diethylcarbamoyl)methoxy]-3-ethoxyphenyl]acetic acid propyl ester, a water-immiscible solvent, an emulsifier, a tonicity modifier, 0.05-0.2% by weight histidine, and water,wherein pH is greater than 7 and wherein composition contains a preservative | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-01-27 | — | — | US | disclosed |
| WO-2004037750-A2 | SHORT-ACTING SEDATIVE HYPNOTIC AGENTS FOR ANESTHESIA AND SEDATION | THERAVANCE, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076079-A1 | Pharmaceutical Compositions Of Short-Acting Sedative Hypnotic Agent | GABRA5, GABRA6, GABRA1 | RXRA 139/4885RXRB 440/4885RXRG 283/4885 |
| US-20090253787-A1 | SHORT-ACTING SEDATIVE HYPNOTIC AGENTS FOR ANESTHESIA AND SEDATION | GABRA5, GABRA6, GABRA2 | RXRA 136/4885RXRB 273/4885RXRG 214/4885 |
| US-20050020674-A1 | Comprising [4-[(N,N-diethylcarbamoyl)methoxy]-3-ethoxyphenyl]acetic acid propyl ester, a water-immiscible solvent, an emulsifier, a tonicity modifier, 0.05-0.2% by weight histidine, and water,wherein pH is greater than 7 and wherein composition contains a preservative | H1-0, H1-4, DDC | RXRA 785/4885RXRB 1213/4885RXRG 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.